Asegua Therapeutics is providing access to hepatitis C therapies with two new drugs: authorized generic of HARVONI® (ledipasvir/sofosbuvir) and authorized generic of EPCLUSA® (sofosbuvir/velpatasvir).

Asegua Therapeutics provides patients support services through Support Path® to help patients with chronic hepatitis C get access to an authorized generic prescription

The new authorized generic of HARVONI® (ledipasvir/sofosbuvir) and authorized generic of EPCLUSA® (sofosbuvir/velpatasvir) are intended to provide greater access to hepatitis C therapies.

The Asegua Co-pay Coupon (“Coupon”) provides financial assistance for the out-of-pocket costs for eligible commercially insured patients as described in the Coupon Benefits above.

2018年9月26日 · Increased market competition has prompted Gilead Sciences to launch authorized generics of their chronic hepatitis C virus (HCV) treatments Epclusa and Harvoni. The generic drugs will be sold through a specially-created subsidiary – named Asegua Therapeutics – starting in early 2019.

WHAT IS ASEGUA THERAPEUTICS? • Asegua Therapeutics is a subsidiary of Gilead Sciences that has launched an AG of EPCLUSA® (sofosbuvir 400 mg/velpatasvir 100 mg) and an AG of HARVONI® (ledipasvir 90 mg/ sofosbuvir 400 mg)

The Gilead Support Path Program offers information and resources to help patients understand coverage and financial options for their prescribed Gilead and Asegua treatments

To complete co-pay enrollment for the authorized generic of EPCLUSA® (sofosbuvir 400 mg/velpatasvir 100 mg tablets) or the authorized generic of HARVONI® (ledipasvir 90 …

2019年6月26日 · The Department of Health and Asegua completed and signed a formal contract for the purchase of Asegua’s hepatitis C medication, the authorized generic of Epclusa, over five years, and for people enrolled in the Medicaid program and incarcerated people in Louisiana.

The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required. This is to inform you of a product recall involving Sofosbuvir and Velpatasvir 400 mg/100 mg Tablets (ag SOF VEL) by Asegua Therapeutics (Asegua).